The Biotron Limited (ASX: BIT) share price soared by 30% today, after the biotechnology company released new data regarding the effectiveness of its lead antiviral drug BIT225, used for fighting HIV-1 infections.
The Biotron share price is on a tear this year, up more than 140% since January to 13 cents.
What did Biotron announce?
This morning, Biotron released data on its HIV-1 drug, BIT225. The data demonstrates how BIT225 enhances the immune response to HIV. Biotron commented that the drug is unique in that it not only inhibits the virus but also augments the immune responses against it.
“The latest results provide key information on how BIT225 directly modifies immune responses to HIV-1 infection. It helps explain the immune changes that we saw in the Phase 2 clinical trial and gives us even more confidence in our product,” said Dr Michelle Miller, Biotron’s managing director.
According to the report, specific cell markers that usually don’t signal the immune system to attack the virus are instead returned to normal. Furthermore, the drug also increases functionality of the immune response by enabling T cells to more around the body and restore immune function.
These results, coupled with those from the Phase 2 clinical trial, further support the continued clinical study of the potential anti-viral and immunological benefits of BIT225 therapy in combination with standard anti-HIV drugs.
How Biotron is helping to combat COVID-19
It has been an exciting year for Biotron, which announced in March that its HIV-1 drug was able to restore immune function in HIV-1 infections. Furthermore, on 6 February Biotron announced plans to test its compounds against coronavirus, observing at the time it had over 30 compounds with good activity against a range of coronaviruses. Some of these compounds were stated to reduce the levels of coronavirus by 90–100% in infected cell cultures.
Biotron’s expertise lies in the design and development of drugs that target virus-encoded proteins known as viroporins. The company’s scientists were the first to identify and publish data showing that the E protein of the coronavirus is viroporin and a good target for antiviral drugs.
The Biotron share price is down on its 52-week high of almost 19 cents (reached in early February), but at its current price of 13 cents a share is up by 73.33% on this time last year.
5 stocks under $5
We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.
And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!
*Extreme Opportunities returns as of June 5th 2020
More reading
- Have $10,000 to invest? I’d pick these ASX shares
- Are Afterpay shares the next Visa?
- Kogan and 1 other ASX share to buy and hold beyond 2025
- ASX 200 falls 0.7%, Qantas and Afterpay make a partnership
- 2 ASX shares I would buy for growth and income
The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Biotron share price rockets 30% on latest antiviral drug data appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/2ZHdZzv
Leave a Reply